AI
ANIK icon

Atria Investments’s Anika Therapeutics ANIK Stock Holding History

Atria Investments’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,096
Closed -$139K – 2010
2025
Q2 		$139K Buy
13,096
+2,118
+19% +$26.7K ﹤0.01% 1950
2025
Q1 		$165K Buy
+10,978
New +$183K ﹤0.01% 1844
2024
Q4 		– Sell
-8,831
Closed -$218K – 1851
2024
Q3 		$218K Buy
+8,831
New +$229K ﹤0.01% 1787
2020
Q1 		– Sell
-3,950
Closed -$205K – 597
2019
Q4 		$205K Buy
+3,950
New +$229K 0.01% 1145
2017
Q4 		– Sell
-4,986
Closed -$289K – 816
2017
Q3 		$289K Sell
4,986
-645
-11% -$33.7K 0.02% 619
2017
Q2 		$278K Buy
5,631
+68
+1% +$3.13K 0.02% 586
2017
Q1 		$242K Buy
5,563
+679
+14% +$32.4K 0.02% 586
2016
Q4 		$239K Buy
+4,884
New +$226K 0.02% 548

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atria Investments's ANIK Position: Q3 2025 in Review

Atria Investments sold out of Anika Therapeutics (ANIK) in Q3 2025, closing a stake of 13,096 shares — an estimated $139K sold.

Atria Investments first reported a position in ANIK in Q4 2016 and held it in 8 quarters. The position peaked at $289K in Q3 2017. 117 funds tracked by Wall St. Rank hold ANIK as of Q3 2025.

  • Atria Investments reported no remaining Anika Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Atria Investments sold 13,096 Anika Therapeutics shares in Q3 2025, an estimated $139K.
  • Atria Investments first reported a position in Anika Therapeutics in Q4 2016 and held it in 8 quarters.
  • Atria Investments's Anika Therapeutics position peaked at $289K in Q3 2017.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2025.

Based on Atria Investments's 13F filing for Q3 2025, filed 6 Nov 2025.